Why the study?
Does bezafibrate therapy improve plasma lipoprotein abnormalities in hypertriglyceridemic subjects?
Population
16 hypertriglyceridemic (HTG) subjects (triglycerides 222-2,500 mg/dl)
Comparison
Bezafibrate therapy vs Baseline
Design
Cohort
Authors
Loading...
Bezafibrate was associated with normalized lipoproteins in hypertriglyceridemia; extends mechanistic data but should not yet change practice.
Does bezafibrate therapy improve plasma lipoprotein abnormalities in hypertriglyceridemic subjects?
Bezafibrate therapy significantly reduces plasma triglycerides and reverses compositional abnormalities in VLDL, LDL, and HDL in hypertriglyceridemic patients.
Eisenberg et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: